CPL-M2-TRZ 10mg (Dual Incretin Research)

One Receptor Wasn’t Enough. So They Added a Second.

Tirzepatide is the first peptide to simultaneously target two incretin receptors — GIP and GLP-1. This dual-agonist approach was a conceptual advance: the hypothesis that activating two convergent pathways would produce greater effects than either one alone.

Why Researchers Study It

• Dual GIP/GLP-1 activation — two convergent incretin pathways
• SURPASS trials — head-to-head vs semaglutide (NEJM 2021)
• SURMOUNT trials — obesity-specific clinical data
• Lipid metabolism — GIP receptor adds independent metabolic signaling

What Makes It Different

Where semaglutide targets one receptor, tirzepatide targets two. The GIP receptor adds a second insulinotropic signal plus lipid metabolism regulation that GLP-1 alone doesn’t provide.

Analytical Documentation

• Purity: Batch-specific Certificate of Analysis (COA) included
• Method: HPLC and/or LC-MS verification
• Storage: Lyophilized — store cool, dry, protected from light